Inhibition of catechol-0-methyltransferase contributes to more stable levodopa plasma levels

Movement Disorders

Volumn 21, Issue 3, 2006, Pages 332-336

  Müller, Thomas ^a   Erdmann, Christoph ^a   Muhlack, Siegfried ^a   Bremen, Dirk ^b   Przuntek, Horst ^a   Woitalla, Dirk ^a  

^a ST JOSEF HOSPITAL   (Germany)

^b Orion Pharma GmbH   (Germany)

Author keywords

Entacapone; Levodopa; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE; CARBIDOPA; CATECHOL DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MONITORING; DRUG STABILITY; DRUG SUBSTITUTION; DYSKINESIA; ENZYME INHIBITION; FEMALE; HUMAN; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; STANDARDIZATION; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TREATMENT OUTCOME; BLOOD; DRUG ANTAGONISM; DRUG COMBINATION; MIDDLE AGED;

ADULT; AGED; ANTIPARKINSON AGENTS; CARBIDOPA; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; DOPAMINE AGONISTS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 33645540098     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20717     Document Type: Article

References (17)

1. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
2. Brooks DJ, Sagar H. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 2003;74:1071-1079.
3. Gershanik O, Emre M, Bernhard G, Sauer D. Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:963-971.
4. Olanow CW, Kieburtz K, Stern M, et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol 2004;61:1563-1568.
5. Gerlach M, van den BM, Blaha C, Bremen D, Riederer P. Entacapone increases and prolongs the central effects of 1-DOPA in the 6-hydroxydopamine-lesioned rat. Naunyn Schmiedebergs Arch Pharmacol 2004;370:388-394.
6. Jenner P. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 2004;62(1 Suppl. 1):S47-S55.
7. Olanow CW, Stocchi F. COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications? Neurology 2004;62(1 Suppl. 1):S72-S81.
8. Müller T, Benz S, Przuntek H. Tapping and peg insertion after levodopa intake in treated and de novo parkinsonian patients. Can J Neurol Sci 2002;29:73-77.
9. Fahn S, Elton R, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, et al., editors. Recent developments in Parkinson's disease II. New York: Macmillan; 1987. p 153-163.
10. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
11. Müller T, Woitalla D, Schulz D, Peters S, Kuhn W, Przuntek H. Tolcapone increases maximum concentration of levodopa. J Neural Transm 2000;107:113-119.
12. Koller W, Guarnieri M, Hubble J, Rabinowicz AL, Silver D. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. J Neural Transm 2005;112:221-230.
13. Müller T, Benz S. Quantification of the dopaminergic response in Parkinson's disease. Parkinsonism Relat Disord 2002;8:181-186.
14. Müller T, Kuhn W, Schulte T, Przuntek H. Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson's disease. Neurosci Lett 2003;339:25-28.
15. van Hilten JJ, Middelkoop HA, Kuiper SI, Kramer CG, Roos RA. Where to record motor activity: an evaluation of commonly used sites of placement for activity monitors. Electroencephalogr Clin Neurophysiol 1993;89:359-362.
16. Muhlack S, Konietzka S, Woitalla D, Przuntek H, Müller T. Simple movement sequences better correlate to levodopa plasma levels than complex ones. J Neural Transm 2004;68(Suppl.):53-60.
17. 123I]-iodolisuride SPET visualizes dopaminergic loss in de-novo parkinsonian patients: is it a marker of striatal presynaptic degeneration? Nucl Med Commun 1997;18:1115-1121.